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Abstract
Background: In early-phase studies with targeted therapeutics and radiotherapy, it may be difficult to decide
whether an adverse event should be considered a dose-limiting toxicity (DLT) of the investigational systemic agent,
as acute normal tissue toxicity is frequently encountered with radiation alone. We have reanalyzed the toxicity data
from a recently conducted phase 1 study on vorinostat, a histone deacetylase inhibitor, in combination with pelvic
palliative radiotherapy, with emphasis on the dose distribution within the irradiated bowel volume to the
development of DLT.
Findings: Of 14 eligible patients, three individuals experienced Common Terminology Criteria of Adverse Events
grade 3 gastrointestinal and related toxicities, representing a toxicity profile vorinostat has in common with
radiotherapy to pelvic target volumes. For each study patient, the relative volumes of small bowel receiving
radiation doses between 6 Gy and 30 Gy at 6-Gy intervals (V6-V30) were determined from the treatment-planning
computed tomography scans. The single patient that experienced a DLT at the second highest dose level of
vorinostat, which was determined as the maximum-tolerated dose, had V6-V30 dose-volume estimates that were
considerably higher than any other study patient. This patient may have experienced an adverse radiation dose-
volume effect rather than a toxic effect of the investigational drug.
Conclusions: When reporting early-phase trial results on the tolerability of a systemic targeted therapeutic used as
potential radiosensitizing agent, radiation dose-volume effects should be quantified to enable full interpretation of
the study toxicity profile.
Trial registration: ClinicalTrials.gov: NCT00455351
Findings
Context
With current advances in molecular radiobiology, strate-
gies for improving efficacy of clinical radiotherapy are
increasingly focused on investigating targeted com-
pounds as radiosensitizing agents. The accepted investi-
gational sequence for clinical evaluation consists of
initial toxicity assessment of the systemic compound in
combination with radiation, and the conventional 3+3
expansion cohort design remains the prevailing method
for conducting phase 1 trials in cancer therapy [1]. In
radiotherapy, the location of the disease predetermines
the potential normal tissues that will be exposed. Unless
the study design mandates that patients’ disease sites are
restricted to specific anatomic sites, the 3+3 expansion
cohort model may be unsuitable for assessing the rate of
adverse events and overall normal tissue toxicity as
study endpoints.
Furthermore, in radiotherapy, toxic complications are
both common and acceptable, and adverse events are
often interrelated. Radiation-induced early toxicity is
commonly experienced as a transient phenomenon
either during the therapy course or within a few weeks
of treatment completion, typically in normal tissues with
a hierarchical proliferative structure, such as the muco-
sal lining of the gastrointestinal tract [2]. When combin-
ing radiation with targeted therapeutics that have the
potential to modulate radiation-induced cellular
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responses, additive or synergistic normal tissue effects
should be anticipated.
It is widely recognized that irradiation of large
volumes is associated with a heightened risk of normal
tissue toxicity. For example, in protocols applying irra-
diation of the bowel with two- to four-field techniques,
moderate to severe acute gastrointestinal toxicity, pri-
marily diarrhea, is observed in a significant fraction of
patients. Furthermore, the probability and severity of
such effects increase with the size of the therapeutic tar-
get volume and the dose per fraction [3]. Recently,
attempts to quantify dose-volume effects within the
small bowel have been reported, and data suggests that
radiation-induced acute small bowel toxicity can be pre-
dicted by threshold estimates for varying dose-volume
combinations [4].
Consequently, studies that are designed as early inves-
tigations into the safety of combining targeted therapeu-
tics with pelvic radiotherapy may be particularly
challenging to conduct as acute bowel toxicity is fre-
quently encountered with radiation alone. In this setting,
it may be difficult to decide whether or not a toxic event
occurring during treatment is greater than might be
expected for either of the therapeutic components and
specifically whether the event should be considered a
dose-limiting toxicity (DLT) of the systemic agent.
We have recently conducted a phase 1 study, PRAVO
- Pelvic Radiation and Vorinostat, on vorinostat (Merck
& Co., Inc., Whitehouse Station, NJ, USA), a histone
deacetylase inhibitor, in combination with pelvic pallia-
tive radiotherapy for advanced gastrointestinal carci-
noma [5], and have experienced methodological
limitations in determining maximum-tolerated dose
(MTD) and DLT. Hence, in the current report, we have
reanalyzed the study toxicity data with emphasis on the
relevance of the dose distribution within the irradiated
bowel volume to the development of DLT. All DLTs
reported by the study patients were gastrointestinal and
related adverse events, representing a toxicity profile
vorinostat has in common with radiotherapy to pelvic
target volumes [6].
Methods
The PRAVO study was approved by the Regional Com-
mittee for Medical and Health Research Ethics and was
performed in accordance with the Declaration of Hel-
sinki. Written informed consent was required for
participation.
The study objective was to determine tolerability of
vorinostat, defined by DLT and MTD, when adminis-
tered concomitantly with palliative radiation to pelvic
target volumes. The principal eligibility criterion was
pelvic carcinoma scheduled to receive palliative radia-
tion to 30 Gy in 3-Gy daily fractions. Other details on
eligibility are given in the initial report [5]. The radio-
therapy was delivered to target volumes (macroscopic
tumor burden, as depicted by magnetic resonance ima-
ging, with appropriate margins) determined by com-
puted tomography (CT)-based conformal planning.
Median values for minimum and maximum doses to the
internal target volume were 28.3 Gy (range 26.1-28.9
Gy) and 31.4 Gy (range 30.8-33.6 Gy), respectively. The
study adopted the standard 3+3 expansion cohort
design, where patients were enrolled onto sequential
dose levels of vorinostat, as previously detailed [5].
Toxicity was recorded continuously during treatment
and was reexamined two and six weeks after treatment
completion, and was graded according to Common Ter-
minology Criteria for Adverse Events version 3.0. DLT
was defined as grade ≥3 toxicity. A treatment delay
longer than one week due to toxicity was also consid-
ered a DLT.
Fourteen of the 16 study patients had treatment-plan-
ning CT scans visualizing the entire abdominal and pel-
vic cavities and were evaluable for this reanalysis.
Individual loops of small bowel were contoured on each
slice of the planning CT scans, enabling the generation
of total small bowel dose-volume histograms [4]. For
each of the 14 patients, the relative volumes of small
bowel receiving radiation doses of 6 Gy to 30 Gy,
defined as V6-V30, were recorded at 6-Gy intervals.
The data reported here is solely descriptive, and no
statistical adaptation has been undertaken.
Results
Patient baseline characteristics and the complete data on
adverse events have been described previously [5]. Of
note, the locations of the radiotherapy target lesions
were heterogeneous within the pelvic cavity or sur-
rounding anatomic structures, and several patients had
multiple targets. Fourteen patients were eligible for rea-
nalysis of the toxicity data with regard to radiation
dose-volume profiles (Table 1).
Six of the 14 patients experienced grade 3 adverse
events; however, in three patients, the reported event
was considered to be unrelated to the study treatment:
one in a patient receiving 200 mg vorinostat and report-
ing a grade 3 acneiform rash following commencement
of cetuximab, and two in patients at 300 mg vorinostat
with pneumonia, who reported grade 3 fatigue that
rapidly resolved on antibiotic treatment.
The remaining three cases of grade 3 adverse events
were considered to be treatment-related and were there-
fore documented as true DLTs. One of six patients
receiving 300 mg vorinostat reported grade 3 anorexia
and fatigue. At 400 mg vorinostat, two of six patients
reported grade 3 diarrhea, with one patient developing
synchronous grade 3 anorexia and hyponatremia and
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the other experiencing grade 3 fatigue and hypokalemia.
Since one of six patients at 300 mg vorinostat and two
of six patients within the 400 mg dose cohort reported a
DLT, the MTD of vorinostat, according to conventional
phase 1 study design, was determined to be 300 mg
once daily.
For each of the 14 patients, data on absolute volumes
of gross tumor, internal radiation target, and total small
bowel, relative volumes of small bowel receiving radia-
tion doses between 6 Gy and 30 Gy at 6-Gy intervals
(V6-V30), and the daily vorinostat dose is summarized
in Table 1. Within the table, patients are listed in des-
cending order with reference to the V6 values. Of parti-
cular note, the single patient that experienced a DLT in
the vorinostat 300 mg dose cohort had the greatest V6,
and all her additional dose-volume estimates (V12-V30)
were considerably higher than in any other patient
assessed.
In the vorinostat 400 mg dose cohort, however, the
radiation dose-volume records for the two patients
reporting DLTs ranked towards the middle of the tabu-
lated list. In these two patients, the relative volumes of
irradiated small bowel across all radiation doses (V6-
V30) appeared to be within the same order of magni-
tude and ranked first and third within the vorinostat
400 mg dose cohort separately. Three of the remaining
four patients in this dose cohort had considerably lower
values of V6-V30.
Because some patients had radiotherapy target lesions
located in anatomic structures outside the pelvic cavity,
such as the perineum or pelvic wall, their irradiated
small bowel volumes were smaller than the internal
radiation target volumes.
Implications
As typically may be the case with phase 1 studies, the
size of the PRAVO study population was small and few
adverse events were recorded. Thus, the resulting data is
descriptive and not subject for expedient handling statis-
tically. Nevertheless, following this reanalysis of the
PRAVO toxicity data, it seems probable that the single
patient reporting a DLT at the vorinostat 300 mg dose
level may have experienced an adverse radiation dose-
volume effect rather than a toxic effect of the investiga-
tional drug. In the remaining four patients within the
300 mg dose cohort, and in all other study patients
reported here, the relative volumes of small bowel
receiving radiation doses of 12-30 Gy (V12-V30) were
substantially smaller. However, our previous conclusion
that vorinostat 300 mg once daily defines the MTD in
this therapeutic setting [5] holds true, since the two
patients (of six) reporting DLTs at 400 mg vorinostat
had radiation dose-volume records (V6-V30) that essen-
tially were indistinguishable from the estimates in
patients without any treatment-related grade 3 adverse
events. These observations suggest that, when applying
an early-phase study design to evaluate tolerability of a
systemic targeted therapeutic combined with radiother-
apy, the contribution of radiation dose-volume effects to
the observed toxicity should be quantified and reported
in a standardized manner to enable full interpretation of
the study toxicity profile.

























87 female 285 648 823.8 79 74 70 67 40 300 anorexia, fatigue
81 female 72.2 380 990.9 63 41 22 18 0 300
66 female 171 483 2292 45 37 19 15 3 200 rash (following
cetuximab)
49 female 89.5 323 1291 43 38 33 25 11 200
47 female 198 414 2440 42 37 34 30 14 300
83 female 197 549 1114 41 29 24 19 3 400 diarrhea, anorexia, hyponatremia
55 male 87.7 867 1811 34 23 18 16 6 400
75 female 36.7 277 1516 31 14 11 8 0 400 diarrhea, fatigue, hypokalemia
62 male 114 324 2180 19 5 3 2 0 400
77 male 153 650 1972 18 7 3 3 1 300 fatigue (during
pneumonia)
45 female 58.1 175 2163 16 7 5 4 0 400
82 male 75.5 330 2946 15 4 1 1 0 300 fatigue (during
pneumonia)
77 female 164 625 1901 5 2 1 0 0 100
85 female 60.1 180 1256 4 2 2 1 0 400
Abbreviations: GTV = gross tumor volume; ccm = cubic centimeter; ITV = internal target volume; SBV = small bowel volume; V6-V30 = the relative volumes of
small bowel receiving radiation doses of 6-30 Gy; DLT = dose-limiting toxicity.
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When applying the standard 3+3 expansion cohort
design to assess relevant normal tissue toxicities in
radiotherapy trials, we propose that the potential disease
site being irradiated should be clearly specified as study
eligibility criterion. Unlike early-phase studies with sys-
temic therapies, where location of disease manifestations
presumably is less critical for evaluation of treatment
tolerability, the anatomic site of the target lesions deter-
mines the normal organs exposed in radiotherapy.
The PRAVO study was designed as an initial investi-
gation examining the safety of a histone deacetylase
inhibitor employed as radiosensitizing component of
pelvic radiotherapy. Importantly, within the study
design, small bowel toxicity was an anticipated outcome
parameter, since single-agent vorinostat is known to be
tolerated at 400 mg daily for continuous dosing, with
the most common side effects being fatigue and gastro-
intestinal toxicities [6]. Consequently, the toxicity pro-
files of pelvic radiation and vorinostat might overlap or
potentially be synergistic. We suggest that in a phase 1
trial setting, where overlapping toxicities between a tar-
geted systemic compound and radiation are anticipated,
it would be highly beneficial if detailed radiation dose-
volume constraints are described within the treatment
protocol.
The pragmatic 3+3 expansion cohort design has been
the prevailing method of documenting adverse events
associated with administration of new drugs, as it
requires no modeling of the dose-toxicity curve beyond
the classical assumption for cytotoxic agents, including
radiotherapy, that toxicity increases with dose [1]. In the
context of combining a systemic targeted agent with
radiotherapy, it is acknowledged that the delivered
radiation dose may on occasion be close to or even at
the limits of normal tissue tolerance. The awareness of
this possibility is a strong argument in favor of precise
dose escalation methods for the systemic agent and/or
radiation schedule, that are simple and convenient to
administer and that equally take account of potential
radiation dose-volume effects.
Learning from this reanalysis of the PRAVO study
outcome data, albeit derived from few reported adverse
events in a small study population, radiation dose-
volume effects should be quantified when reporting
early-phase trial results on the tolerability of a systemic
targeted therapeutic used as potential radiosensitizing
agent. We believe there are methodological require-
ments in future early-phase trials utilizing novel radio-
sensitizers, particularly with regard to patient eligibility
criteria, predetermining specific tumor sites and, as a
consequence, the radiotherapy target volume.
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